<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04784507</url>
  </required_header>
  <id_info>
    <org_study_id>10840098-604.01.01-E.55105</org_study_id>
    <nct_id>NCT04784507</nct_id>
  </id_info>
  <brief_title>En-Bloc Resection of Bladder Tumors</brief_title>
  <official_title>En-Bloc Resection of Bladder Tumors: a Multicentric Safety and Feasibility Trial (IDEAL Phase II) vs Conventional Resection of Bladder Tumors?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Betul Kartal</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bağcılar Eğitim ve Araştırma Hastanesi</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medipol University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Observational data shows that &quot;en bloc&quot; resection of bladder tumor (EBR-BT) may entail&#xD;
      advantages when compared with conventional transurethral bladder tumor resection (TURBT).&#xD;
      EBR-BT has the potential to increase the rate of correct staging and accurate assignment of&#xD;
      risk-classification in non-muscle-invasive bladder cancer (NMIBC) and to avoid re-TURBT in a&#xD;
      considerable number of high-grade NMIBC by demonstrating total macro and microscopic&#xD;
      eradication of the primary tumor and to provide the basis for a correct treatment based on a&#xD;
      correct stage.&#xD;
&#xD;
      Following the rules of the IDEAL collaboration evaluation and stages of surgical innovation&#xD;
      and considering EBR-BT as a surgical technical innovation, the investigators designed a&#xD;
      multi-institutional, stage 2a/b study on feasibility (procedural success), safety (including&#xD;
      pathology features), and short-term efficacy of EBR-BT and as proof of concept on the&#xD;
      reliability of NMIBC staging.&#xD;
&#xD;
      Main objective: to prospectively assess the pathological efficacy of EBR-BT in the staging of&#xD;
      bladder cancer and the clinical efficacy at short-term recurrence-free survival.&#xD;
&#xD;
      Secondary objectives: To assess the clinical efficacy at short-term (3-months) of EBR-BT, and&#xD;
      to compare efficacy in the staging of the EBR-BT with the conventional TURBT.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      En-bloc resection of bladder tumors (EBR-BT) has been showing certain advantages over&#xD;
      conventional transurethral resection technique (TURBT) in non-muscle-invasive bladder cancer.&#xD;
      These advantages consist mainly in the reduction of obturator nerve reflex and obtention of&#xD;
      surgical samples according to oncological principles. Advantages in terms of tumor recurrence&#xD;
      in the short-term, when compared with TURBT, remain uncertain. Herein several randomized&#xD;
      control trials aim to assess comparative outcomes in the short and long term.&#xD;
&#xD;
      A higher rate of detrusor muscle is found in the EBR-BT samples than in the conventional&#xD;
      samples resulting in a better staging and at least theoretically the need for fewer re-TURBT&#xD;
      indications. However, a detailed and scrupulous description of the histopathological samples&#xD;
      is lacking and, it is assumed that the presence of detrusor in the sample without solution of&#xD;
      continuity with submucosa and tumor is sufficient to stage. As in surgical samples of other&#xD;
      organs, the objective of EBR-RT is not only to obtain detrusor, but also clean margins that&#xD;
      ensure the radicality of the tumor.&#xD;
&#xD;
      The hypothesis of the investigators' is that EBR-BT will results in an increased rate of&#xD;
      pathological specimen with the presence of detrusor muscle and free-tumor margins, hence a&#xD;
      more accurate stage than TURBT and a decrease in 3-months recurrence at short-term (3 months)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2020</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathological Staging</measure>
    <time_frame>Immediately after the intervention</time_frame>
    <description>Staging of NMIBC is defined by the presence of sufficient detrusor in the EBR-BT specimens, the status of the margins, presence of a tumor and /or CIS in the mucosal margins, the status of the detrusor margin, and suspicion of instability in mucosa free of tumor.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recurrence at 3 months</measure>
    <time_frame>3 months</time_frame>
    <description>Recurrence free survival at 3-months (absence of visible tumors at the site of the previous resection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Operative Complications</measure>
    <time_frame>intraoperative</time_frame>
    <description>Rate of operative complications (estimated bleeding, bladder perforation, obturatory reflex, tumor fragmentation, conversion to conventional TURBT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perioperative Complications</measure>
    <time_frame>Up to 90 days</time_frame>
    <description>Postoperative complications according to Clavien-Dindo classification</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Bladder Neoplasm</condition>
  <arm_group>
    <arm_group_label>En Bloc Resection Bladder Tumor (Any energy source)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with suspicion of NMIBC (primary or recurrent) that underwent en bloc resection (EBRT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional Transurethral Resection Bladder Tumor (Mono/Bipolar)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with suspicion of NMIBC (primary or recurrent) that underwent conventional TURBT</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>En Bloc Resection</intervention_name>
    <description>En bloc transurethral resection of bladder tumor (EBR-BT) using any energy source (laser and bipolar or monopolar energy)</description>
    <arm_group_label>En Bloc Resection Bladder Tumor (Any energy source)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Conventional Transurethral Resection Bladder Tumor (Mono/Bipolar)</intervention_name>
    <description>Conventional Transurethral Resection Bladder Tumor (Mono/Bipolar)</description>
    <arm_group_label>Conventional Transurethral Resection Bladder Tumor (Mono/Bipolar)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age: 18 years old and older (adult, older adult) Sexes: All Accepts healthy&#xD;
             volunteers: No&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  Patients aged 18 and older presenting with suspicion of primary or recurrent&#xD;
             Non-muscle invasive bladder cancer (NMIBC)&#xD;
&#xD;
          -  Tumor size estimated by cystoscopy ≤ 3 cm&#xD;
&#xD;
          -  Solitary or multiple tumors (up to 3 in number)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Tumor size &gt; 3 cm of maximum dimeter&#xD;
&#xD;
          -  Patient with severe systemic disease (ASA III+)&#xD;
&#xD;
          -  Location on the anterior bladder wall and/ or anterior bladder neck (relative&#xD;
             contraindication depending on accessibility)&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Histological diagnosis other than NMIBC urothelial bladder cancer&#xD;
&#xD;
          -  Presence or history of previous upper-tract urinary cancer (UTUC)&#xD;
&#xD;
          -  Presence of positive cytology without macroscopic identifiable bladder tumor&#xD;
&#xD;
          -  Life expectancy &lt; 1 year&#xD;
&#xD;
          -  Non-reversible coagulopathy&#xD;
&#xD;
          -  Bladder tumor detected during intravesical BCG therapy&#xD;
&#xD;
          -  Tumor multiplicity (&gt; 3 tumors)&#xD;
&#xD;
        Contacts and locations:&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Rahim Horuz</last_name>
    <phone>+90533 934 38 50</phone>
    <email>rhoruz@medipol.edu.tr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Betul Kartal</last_name>
    <email>bbkartal@medipol.edu.tr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Bagcilar Education and Research Hospital</name>
      <address>
        <city>Istanbul</city>
        <state>Bagcilar</state>
        <zip>34200</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bagcilar</last_name>
      <phone>(0212) 440 40 00</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medipol Mega University Hospital</name>
      <address>
        <city>Istanbul</city>
        <state>Bagcilar</state>
        <zip>34214</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Medipol</last_name>
      <phone>444 7 044</phone>
    </contact>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>February 26, 2021</study_first_submitted>
  <study_first_submitted_qc>March 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2021</study_first_posted>
  <last_update_submitted>April 12, 2021</last_update_submitted>
  <last_update_submitted_qc>April 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Medipol University</investigator_affiliation>
    <investigator_full_name>Betul Kartal</investigator_full_name>
    <investigator_title>Research Coordinator</investigator_title>
  </responsible_party>
  <keyword>Urinary Bladder Neoplasms</keyword>
  <keyword>Urologic Neoplasms</keyword>
  <keyword>Urogenital Neoplasms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Data will be provided by request according to the primary objectives of the IPD study and according to the availability in the present trial</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

